The effect of dexamethasone on post-tonsillectomy nausea, vomiting and bleeding

Jochen P. Windfuhr¹, Yue-Shih Chen², Evan J. Propst³, Christian Güldner⁴

Abstract

It has been stated, that the administration of Dexamethasone has an impact on the morbidity following tonsillectomy.

Objective: To re-calculate the blood values for Dexamethasone when given as fixed doses and to evaluate the effect of Dexamethasone on post-operative nausea, vomiting and bleeding rates following tonsillectomy.

Materials and methods: The charts of 272 children (2-15 years) who had undergone tonsillectomy were analyzed. The rates of post-operative nausea, vomiting and bleeding in relation to Dexamethasone were calculated in general and different doses (0 mg/kg, <0.15 mg/kg, >0.15 mg/kg).

Study design: Retrospective cohort study.

Results: Dexamethasone was administered in 121 children (43.7%) according to the preference of the anesthesit (mean dose: 0.2 +/- 0.12 mg/kg; range: 0.04 - 0.62 mg/kg). There was no significant difference in nausea and vomiting (p=0.953) or bleeding (p=0.827) across groups receiving or not receiving Dexamethasone. Stratification into three different groups of Dexamethasone concentration also did not identify a dose-related risk of postoperative nausea or vomiting (p=0.98) or bleeding (p=0.71).

Conclusion: At least under common non-controlled conditions in the clinic, Dexamethasone does not appear to have an effect on nausea or vomiting or bleeding following tonsillectomy.

Keywords: dexamethasone, hemorrhage, postoperative complications, tonsillectomy.
INTRODUCTION

Several meta-analyses investigating morbidity following tonsillectomy have demonstrated that under controlled conditions a single intravenous dose of Dexamethasone (DX) is an effective, safe and inexpensive method of reducing the incidence of postoperative nausea and vomiting (PONV) following tonsillectomy in children. Unfortunately, there is substantial variability across these studies with respect to design, surgical technique, method of acquiring hemostasis and age of patients. Recently, Czarnetky et al identified a dose-dependent increased rate of post-tonsillectomy hemorrhage following administration of DX. In their study, 50 children were given either a placebo or one of three different concentrations of DX (0.05, 0.15 or 0.5 mg/kg). None of the children in the placebo group required surgical intervention for hemostasis, whereas children in all other DX groups required surgical intervention for hemostasis (5.7%; 2%; 8% respectively).

At the primary investigator’s institution, the decision to administer DX during tonsillectomy is determined by the personal anesthetist’s preference. The goal of the present study was to determine the effect of DX on PONV and bleeding following tonsillectomy from a clinical situation thus maybe better mimic what effect routinely given Dexamethasone would have in ordinary praxis. We therefore calculated the exact blood values for DX related to the individual patient’s weight in this study to clarify, whether or not the values vary significantly in this patient population. This would limit the value of conclusions drawn from studies with administration of DX in fixed doses. Moreover, we hypothesized that the administration of DX would result in a lower rate of PONV but not to cause an increased rate of bleeding.

MATERIAL AND METHODS

The study was in accordance with the requirements of the associated IRB. The charts of 385 continuous pediatric patients (age < 15 years) who had undergone tonsillectomy, with or without adenoidectomy between January 2008 and December 2009 were reviewed. Children who had undergone partial (intracapsular) tonsillectomy (n=108) or who had received methylprednisolone instead of DX (n=5) were excluded from the analysis. Included patients (n=272) were otherwise healthy without a predisposition to bleeding, such as immunodeficiency, diabetes, gastritis, peptic ulcer, cardiovascular, arterial hypertension, malignant or renal diseases or on therapy with corticoids, anti-emetics, anti-histaminics or aspirin.

Patients were premedicated with oral midazolam 0.5 mg/kg 20 minutes before transportation to the operating theatre. All procedures were performed under general anesthesia with oral intubation. Anesthesia was induced with one of three volatile agents (isoflurane, sevoflurane, desflurane). An intravenous line was placed and lactated Ringer’s solution infused after the eyelash reflex had disappeared. Endotracheal intubation was facilitated by 0.1 mg/kg pancuronium. All children received paracetamol 15 mg/kg per rectum. Fentanyl was given according to the preference of the anesthetist. Anesthesia was maintained with volatile agents or propofol with oxygen and N2O. Adrenalin-containing local anesthetic agents were never used intraoperatively. Tonsillectomies were performed using a cold technique, dissecting the tonsils with scissors, raspatory and removing the inferior pole with a snare. Hemostasis was obtained with suture ligation and bipolar cautery where required. DX was administered per each anesthetist’s preference on a case-by-case basis. Patients were given either one half (4 mg) or a full (8 mg) vial of DX. The dose of DX administered was retrospectively calculated for each patient (mg/kg).

Children were extubated in the operating theatre and then transported to the postanesthesia care unit when they were awake and responded to verbal stimuli. They were closely monitored for 2 hours and transported to the ward when vital signs were stable, pain was controlled, and they did not have vomiting or bleeding. Piritramid was administered in 103 children on demand for additional pain control in the postoperative care unit.

Patients were admitted for approximately four days. Episodes of PONV and bleeding were documented.

Statistical analysis was carried out using SPSS statistical package (SPSS 16.0.2 for Windows). Non-parametric data were analyzed using Chi-square-test for categorical data and Mann-Whitney-U-test for continuous data with significance determined as \( p < 0.05 \). In addition to investigating the effect of previously reported cut-off doses of DX on PONV and bleeding following tonsillectomy, we attempted to determine a cut-off dose of DX above which the risk of PONV or bleeding was increased.

RESULTS

There were 272 children included in this study (129 male, 143 female). The mean age of patients was 7.43 +/- 4.3 years (range 2 - 15 years). DX was administered to 121 (43.7%) children either as one half or a full vial. The mean dose of DX given (calculated retrospectively based on weight) was 0.2 +/- 0.12 mg/kg (range 0.04 - 0.62 mg/kg). Five children who were excluded from this study received methylprednisolone in high doses (100 or 250 mg) instead of DX. Nausea or vomiting was experienced by 62 of 272 (22.8%) patients, 28 of whom (45.2%) had received DX. There was no significant difference in nausea or vomiting across groups receiving or not receiving DX (\( p=0.953 \)). Further analysis revealed that 6 of 272 patients (2.2%) had nausea without vomiting, 4 of whom had received DX (doses were 0.05, 0.12, 0.15 and 0.17 mg/kg). There was no difference in nausea across groups receiving or not...
receiving DX (Chi-square test, \(p = 0.827\)). 56 of 272 patients (20.6%) had vomiting without nausea, 24 of whom (42.9%) had received DX (mean dose 0.16 +/-0.09 mg/kg, range 0.07 - 0.44 mg/kg). There was no difference in vomiting across groups receiving or not receiving DX (Chi-square test, \(p = 0.953\)). Evaluation of the effect of DX dose (0 vs. <0.15 vs. \(\geq\)0.15 mg/kg) on postoperative nausea or vomiting did not reveal a difference across groups (Chi-square test, \(p = 0.98\); Table 1 and 2). 79 children received fentanyl 1\(\mu\)g/kg while 198 children did not. Anesthesia was maintained with volatile agents and oxygen as single agents to maintain anesthesia in 135 children with (n=220) or without (n=57) \(\text{N}_2\text{O}\). Maintenance of anesthesia was achieved with propofol in 142 patients, with (n=118) or without (n=24) volatile agents, again, with (n=98) or without (n=44) \(\text{N}_2\text{O}\). 229 of the 272 children received piritramid perioperatively, of whom 104 had received DX (45.4%). Piritramid was not administered in 48 of the 272 patients of whom 22 had received DX (45.8%). The effect of DX to prevent nausea was statistically insignificant (\(p = 0.827\); Chi-square-test).

There was no significant association of postoperative nausea and/or vomiting and anesthetic drugs such as fentanyl (\(p = 0.07\)), piritramid (\(p = 0.026\)) or \(\text{N}_2\text{O}\) (\(p = 0.406\)).

### Hemorrhage from the tonsillectomy site occurred in 22 patients, surgical intervention was required in 17 of 272 patients (6.3%), 7 of whom (41.2%) had received DX (table 3). Primary bleeding (<24 h) was documented in 7 cases and secondary bleeding (>24 h) in 10 children. Two children had more than one episode of secondary bleeding (postoperative day 7/12 and 8/10, respectively). One of these children had received 0.15 mg DX/kg, the second no DX. There was no difference in post-tonsillectomy hemorrhage across groups receiving or not receiving DX (\(p = 0.827\)). Evaluation of the effect of DX dose on postoperative tonsillectomy hemorrhage did not identify a dose-related risk of postoperative bleeding (\(p = 0.711\); table 4).

We were unable to determine a cut-off dose of DX above which the risk of PONV or bleeding was increased due to the large variability of DX doses administered.

### DISCUSSION

Previous studies investigating the effect of intravenously administered DX on nausea and vomiting following tonsillectomy have found promising results\(^2\text{-}\text{20}\). In these studies, DX was most commonly administered as a single intravenous dose before tonsil dissection. In these studies, administered doses were 4\(\text{mg}\), 8\(\text{mg}\), 10\(\text{mg}\) or 20 \(\text{mg}\) and the doses were related to the body weight ranging from 0.15\text{-}0.27, 0.5\text{-}6, 13\text{-}18, 19, 28, 29, 0.7\text{-}0.9 to 1\text{-}5, 9, 10, 17, 31, 32 mg/kg. In some studies, a dose of 8\(\text{mg}\), 13, 14, 26, 29, 33, 10\(\text{mg}\), 12\(\text{mg}\), 15\(\text{mg}\), 16\(\text{mg}\), 19, 20, 25\(\text{mg}\), 24\(\text{mg}\) or 50 \(\text{mg}\) was injected with the additional goal of reducing post-tonsillectomy pain\(^2,7, 9, 10, 12, 14\text{-}17, 19, 20, 22, 24, 25, 35\text{-}39\). Unfortunately, there is great variability across studies, making it difficult to draw any conclusions.

Czarnetzki et al were the first to report a dose-related increased risk of post-tonsillectomy hemorrhage following the administration of DX.\(^4\) Patients in this study

### Table 1. Age distribution in three subpopulations according to specified DX values

| age (years) | no DX | DX < 0.15 mg/kg | DX \(\geq\) 0.15 mg/kg | total |
|------------|-------|----------------|----------------|-------|
| 1          | 1 (50%) | 0 (0%) | 1 (50%) | 2 |
| 2          | 7 (70%) | 2 (20%) | 1 (10%) | 10 |
| 3          | 23 (55%) | 12 (26%) | 7 (19%) | 42 |
| 4          | 25 (63%) | 12 (30%) | 1 (7%) | 40 |
| 5          | 19 (48%) | 12 (30%) | 2 (7%) | 40 |
| 6          | 6 (35%) | 6 (35%) | 1 (30%) | 17 |
| 7          | 7 (46%) | 6 (31%) | 3 (23%) | 13 |
| 8          | 5 (36%) | 2 (14%) | 5 (70%) | 14 |
| 9          | 7 (63%) | 3 (27%) | 1 (10%) | 11 |
| 10         | 2 (25%) | 3 (38%) | 3 (37%) | 8 |
| 11         | 4 (50%) | 2 (25%) | 2 (25%) | 8 |
| 12         | 5 (42%) | 6 (50%) | 1 (8%) | 12 |
| 13         | 5 (50%) | 5 (50%) | 0 (0%) | 10 |
| 14         | 15 (68%) | 4 (18%) | 3 (14%) | 22 |
| 15         | 21 (91%) | 2 (9%) | 0 (0%) | 23 |
| total      | n=151 | n=75 | n=46 | n=272 |

Three subgroups were compared according to the calculated concentration of dexamethasone vs. age.

### Table 2. Incidence of PONV with specified DX values

|                   | no DX  | DX < 0.15 mg/kg | DX \(\geq\) 0.15 mg/kg |
|-------------------|--------|----------------|----------------|---|
| mean (mgDX/kg)    | 0      | 0.10           | 0.26            |
| median (mgDX/kg)  | 0      | 0.11           | 0.20            |
| std (\(\pm\)mgDX/kg)  | 0     | 0.03         | 0.13            |
| min; max (mgDX/kg) | 0     | 0.04; 0.14    | 0.15; 0.62      |
| PONV              | 117 (77%) | 58 (77%)    | 35 (78%)        |
| PONV              | 34 (23%) | 17 (23%)    | 11 (22%)        |
| total             | n=151 | n=75 | n=4 |

Comparison of the three subgroups 0 vs. <0.15 and \(>0.15\) mg/kg could not identify a dose-related risk of or nausea and vomiting that reached statistical significance (\(p = 0.98\)).
received a placebo or one of three different concentrations of DX (0.05; 0.15 or 0.5 mg/kg). Due to the large variability in dose of DX administered in the present study, we decided first to determine if there was any effect of DX on PONV or bleeding, and then investigate the dose-response relation of DX using similar cut-off values similar to those used by Czarnetzki (0 mg/kg, <0.15 mg/kg, >0.15 mg/kg). In contrast to standardized but somewhat artificial conditions of contemporary studies, our case-controlled study evaluated outcomes following tonsillectomy under common clinical conditions. Because guidelines regarding the administration of DX are not yet standardized at our institution and the decision to administer DX is at the discretion of the anesthetist, a retrospective case-controlled study could be conducted. The present study included 272 children with a mean age of 7.43 years which compares to the majority of studies published in the literature (table 4). When administered, the mean dose of DX was 0.2 mg/kg with a range of 0.04 to 0.62 mg/kg per dose. Those authors who administered DX not in relation to weight but as a fixed dose did not calculate the effective dose. The results of the present study indicate that the effective dose is significantly influenced by weight even in a pediatric population which compounds comparison with more sophisticated studies. The median effective dose of 0.2 mg/kg may be lower than calculated in most of the studies (table 4). However, evidence has been given, that higher blood concentrations are not associated with an increased benefit.

The rate of PONV in the present study was 23% with or without DX. This rate is lower than reported in comparable groups (table 5). There was no difference in nausea or vomiting across groups receiving or not receiving DX in the present study. This finding is supported by a number of well-designed prospective studies and refuted by others. For example, results contrast with Karaman who found a dose-dependent decrease in PONV rates following administration of DX. Even though DX dose levels in the present study (0.62 mg/kg) did not attain concentrations of as high as those administered by Karaman (0.7 mg/kg), doses in the present study were close enough that one would expect to see some effect. This reasoning is supported by Kim et al who verified in a double-blinded, prospective randomized study on 125 children that DX doses of 0.0625 mg/kg, 0.125, 0.25, 0.5 and 1 mg/kg are equally effective in reducing PONV rates.

The post-tonsillectomy hemorrhage rate requiring surgical intervention in the present study was 6.3%. When the five patients who experienced minor episodes of bleeding were included, the post-tonsillectomy bleed rate increased to 8.1%. Rates in the literature vary significantly (table 4) which may also result from different surgical techniques, length of follow-up and definitions of post-tonsillectomy hemorrhage. The rate of post-tonsillectomy hemorrhage in the present study is higher than reported previously which appears attributable to the use of electrosurgery either for dissection or hemostasis. There was no difference in post-tonsillectomy hemorrhage rates across groups receiving or not receiving DX in the present study which is only partly supported by other authors (table 4).

| Patient | age | DX (mg/kg) | PONV | PTH (day) |
|---------|-----|------------|------|----------|
| 1.      | 4   | 0.4        |      |          |
| 2.      | 3   | 0.11       |      |          |
| 3.      | 15  | 0          |      |          |
| 4.      | 9   | 0          | Yes  |          |
| 5.      | 5   | 0          |      |          |
| 6.      | 4   | 0.14       |      |          |
| 7.      | 8   | 0          |      |          |
| 8.      | 14  | 0          |      | 1.       |
| 9.      | 5   | 0.09       |      | 2.       |
| 10.     | 7   | 0.09       |      | 3.       |
| 11.     | 13  | 0.061      |      | 3.       |
| 12.     | 8   | 0          |      | 3.       |
| 13.     | 11  | 0          |      | 5.       |
| 14.     | 9   | 0          |      | 6.       |
| 15.     | 3   | 0          | Yes  | 7. +12.  |
| 16.     | 3   | 0.15       |      | 8. +10.  |
| 17.     | 8   | 0          |      | 9.       |
| 18.     | 12  | 0.19       |      | 8.*      |
| 19.     | 14  | 0          |      | 1.*      |
| 20.     | 15  | 0          |      | 1.*      |
| 21.     | 3   | 0.62       |      | 7.*      |
| 22.     | 6   | 0.15       |      | 5.*      |

| no DX | DX< 0.15 mg/kg | DX> 0.15 mg/kg |
|-------|----------------|---------------|
| Uneventful | 139 (92%) | 70 (93%) | 41 (89%) |
| postoperative bleeding | 12 (8%) | 5 (7%) | 5 (11%) |
| Total | n=151 | n=75 | n=46 |
| Author          | age (DX; control group) | N (DX; control group) | bleeding rate (DX; control group) | PONV rate (DX; control group) | DX dose | dissection technique | hemostasis technique |
|-----------------|--------------------------|------------------------|-----------------------------------|-------------------------------|---------|----------------------|---------------------|
| Catlin44        | 4-6; 5-12                | 10; 15                 | 20%; 6.7%                         | ns                            | 8 mg/m2 | cold                 | E                   |
| Volk23          | 6.9; 7.0                 | 25; 24                 | 8.0%; 4.2%                        | ns                            | 10 mg   | cold                 | E                   |
| Tewary45        | 22; 21 (median)          | 40; 42                 | 0%                                | ns                            | 4 mg    | cold                 | suture ligation     |
| Fields22        | 24.7; 23.7               | 29; 29                 | 0%                                | ns                            | 8 mg    | cold                 | suture ligation     |
| Ohlms28         | 7.0; 6.9                 | 34; 35                 | 8.8%; 0%                          | 35%, 43%                      | 0.5 mg/kg; max. 12 mg | cold | E |
| Splinter26      | 6.9; 6.9                 | 63; 70                 | 0%                                | 40%; 71%                      | 0.15 mg/kg; max. 8 mg | ns | ns |
| April8          | 6.5; 7.2                 | 41; 39                 | 2.4%; 2.6%                        | 4.8%; 25.6%                   | 1 mg/kg; max. 16 mg | E | E |
| Tom10           | 1-18 (mean: 5.64)        | 26; 32                 | 3.8%; 6.3%                        | 4%; 48%                       | 1 mg/kg; max. 10 mg | E | E |
| Pappas7         | 6.0; 5.8                 | 63; 65                 | 0%                                | 48%; 88%                      | 1 mg/kg; max. 25 mg | E | E |
| Car24           | 26.9; 27.6               | 15; 14                 | 6.7%; 14.3%                       | ns                            | 20 mg   | E | E |
| Vosdoganis11    | 5.0; 5.7                 | 22; 19                 | 0%                                | 45%; 63%                      | 0.4 mg/kg; max. 8 mg | ns | ns |
| Aouad13         | 5.1; 4.6                 | 53; 53                 | 0%                                | 23%; 51%                      | 0.5 mg/kg; max. 8 mg | E | E |
| Stewart46       | >16                      | 104; 48                | 17.3%; 27.1%                     | 23%; 30%                      | 8 mg , 2 mg postop; 2x2 mg day 1-4; 2 mg day 5-8 | E | ns |
| Giannoni47      | (3-15)                   | 25; 25                 | 8%; 4%                            | 28%; 36%                      | 1.0 mg/kg; max. 16 mg | E after LA | E |
| Elhakim33       | 5.2; 5.1                 | 55; 55                 | 0%                                | 20%; 56%                      | 0.5 mg/kg; max. 8 mg | E | E |
| Al-Shehri16     | 18-35                    | 15; 15                 | 0%                                | 0%; 13%                       | 3 x 8 mg/24 h | E | E |
| Hanasono17      | 5.7; 5.9                 | 106; 113               | 2.8%; 0.9%                        | 1.2; 2.1 episodes of emesis   | 1 mg/kg; max. 50 mg | E | cold |
| Celiker48       | 5.3; 6.1; 5.9 vs. 5.8    | 26; 27; 24 vs. 25      | 0%                                | 27%; 37%; 29% vs. 36%         | 0.15; 0.1; 0.05 vs. 0 mg/kg; max. 8 mg | cold | suture ligation |
| Samarkandi18     | 7.2; 7.2                 | 29; 31                 | 0%                                | 37.9%; 74.2%                  | 0.5 mg/kg | E | E |
| Malde25         | 12; 15                   | 45; 45                 | 0%; 1.1%                          | 22%; 29%                      | 0.15 mg/kg | cold | suture ligation |
| McKean20        | 23; 26                   | 24; 22                 | 0%                                | 29%; 77%                      | 10 mg   | cold | suture ligation |
| Kaan19          | 7.6; 9.3                 | 32; 30                 | 0%                                | 19%; 33%                      | 0.5 mg/kg; max. 16 mg | cold | suture ligation |
| Fazel29         | 9.5; 10.1                | 50; 50                 | 0%                                | 25%; 62                       | 0.5 mg/kg; max. 8 mg | ns | ns |
| Czarnetzki6     | 6; 5; 6 vs. 6 (median)   | 53; 54; 52 vs. 54      | 11%; 4%; 24% vs. 4%               | 38%; 24%; 12% vs. 44%         | 0.05; 0.15; 0.5 vs. 0 mg/kg; max. 20 mg | cold or E after LA | suture ligation or E |
| Karaman30       | (5.9)                    | 100; 50                | 0%                                | 8%; 4%; 80%                   | 0.2 mg/kg; 0.7 mg/kg; max. 25 mg | ns | ns |
| this study      | 7.0; 7.78                | 126; 151               | 7.9%; 7.9%                        | 22.5%; 22.2%                  | 2 mg (<20 kg); 4 mg(>20 kg) | cold | suture ligation |

E=electrosurgery; cold=dissection of the tonsils with raspatory, scissors; LA=local infiltration of local anesthetics prior to tonsil dissection; ns=not stated; age in brackets indicates that ages of the subgroups were specified;
Postoperative vomiting was associated in only 1 of the 22 cases with major bleeding (5.4%) and in no case with minor bleeding suggesting that vomiting itself is not likely a risk factor for post-tonsillectomy hemorrhage. This contrasts with previous reports of vomiting leading to excessive hemorrhage.

The present study has some limitations which have to be considered. First, it is a retrospective observational study. Although it reports from a clinical situation and thus maybe better mimic what effect routinely given Dexamethasone would have in ordinary praxis its weakness is, that other factors that can influence PONV are not controlled. However, multivariate ANOVA-analysis was unable to detect dexamethasone or one of the various anesthetic agents as a risk factor for PONV in our study population (data not shown). Second, the large amount of variability in the dose of DX administered. In an attempt to overcome this limitation, doses of DX were stratified into three groups for analysis. Even though stratification values were selected based on previously reported values, analysis based on different cut-off values may yield different results. We were unable to determine a cut-off dose of DX above which the risk of PONV or bleeding was increased due to the large variability of DX doses administered.

**CONCLUSION**

The administration of fixed doses of Dexamethasone results in significant differences of blood values (factor 15.5). At least under non-controlled conditions in the clinic, Dexamethasone appears not to have an effect on nausea or vomiting or bleeding following tonsillectomy.

**REFERENCES**

1. Steward DL, Welge JA, Myer CM. Steroids for improving recovery following tonsillectomy in children. Cochrane Database Syst Rev. 2003(3):CD000997.
2. Bolton CM, Myles PS, Nolan T, Sterne JA. Prophylaxis of postoperative vomiting in children undergoing tonsillectomy: a systematic review and meta-analysis. Br J Anaesth. 2006;97(5):593-604.
3. Afman CE, Welge JA, Steward DL. Steroids for post-tonsillectomy pain reduction: meta-analysis of randomized controlled trials. Otalaryngol Head Neck Surg. 2006;134(2):181-6.
4. Steward DL, Welge JA, Myer CM. Do steroids reduce morbidity of tonsillectomy? Meta-analysis of randomized trials. Laryngoscope. 2001;111(10):1712-8.
5. Goldman AC, Govindaraj S, Rosenfeld RM. A meta-analysis of DXmethasone use with tonsillectomy. Otolaryngol Head Neck Surg. 2000;123(6):682-6.
6. Czarnecki C, Elia N, Lysakowski C, Dumont L, Landis BN, Giger R, et al. DXmethasone and risk of nausea and vomiting and postoperative bleeding after tonsillectomy in children: a randomized trial. Jama. 2008;300(22):2621-30.
7. Pappas AI, Sukhani R, Hotaling AJ, Mikat-Stevens M, Javorski JJ, Donzelli J, et al. The effect of preoperative DXmethasone on the immediate and delayed postoperative morbidity in children undergoing adenotonsillectomy. Anesth Analg. 1998;87(1):57-61.
8. Splinter W, Roberts DJ. Prophylaxis for vomiting by children after tonsillectomy: DXmethasone versus perphenazine. Anesth Analg. 1997;85(3):534-7.
9. April MM, Callan ND, Nowak DM, Haushof MA. The effect of intravenous DXmethasone in pediatric adenotonsillectomy. Arch Otolaryngol Head Neck Surg. 1996;122(2):117-20.
10. Tom EW, Templeton JJ, Thompson ME, Marsh RR. DXmethasone in adenotonsillectomy. Int J Pediatr Otorhinolaryngol. 1996;57(2):115-20.
11. Vosdoganis F, Baines DB. The effect of single dose intravenous DXmethasone in tonsillectomy in children. Anaesth Intensive Care. 1999;27(5):489-92.
12. Palme CE, Tomasevic P, Polil DV. Evaluating the effects of oral prednisolone on recovery after tonsillectomy: a prospective, double-blind, randomized trial. Laryngoscope. 2000;110(12):2000-4.
13. Aoudat MT, Siddik SS, Rizk LB, Zaytoun GM, Baraka AS. The effect of DXmethasone on postoperative vomiting after tonsillectomy. Anesth Analg. 2001;92(3):636-40.
14. Elhakim M, Ali NM, Rashid I, Rad MK, Refat M. DXmethasone reduces postoperative vomiting and pain after pediatric tonsillectomy. Can J Anaesth. 2003;50(4):392-7.
15. Kaygusuz I, Susman N. The effects of DXmethasone, bupivacaine and topical lidocaine spray on pain after tonsillectomy. Int J Pediatr Otorhinolaryngol. 2003;67(7):737-42.
16. Al-Shahri AM. Steroid therapy for posttonsillectomy symptoms in adults: a randomized, placebo-controlled study. Ann Saudi Med. 2004;24(5):365-7.
17. Hanasono MM, Lalakea ML, Mikulec AA, Shepard KG, Wells V, Messner AH. Perioperative steroids in tonsillectomy using electrocautery and sharp dissection techniques. Arch Otolaryngol Head Neck Surg. 2004;130(8):917-21.
18. Samarkandi AH, Shaikh MA, Ahmad RA, Almamr AM. Use of DXmethasone to reduce postoperative vomiting and pain after pediatric tonsillectomy procedures. Saudi Med J. 2004;25(11):1636-9.
19. Kaan MN, Odabasi O, Gezer E, Daldal A. The effect of preoperative DXmethasone on early oral intake, vomiting and pain after tonsillectomy. Int J Pediatr Otorhinolaryngol. 2006;70(1):73-9.
20. McKean S, Kochulas X, Kelleher R, Dockery M. Use of intravenous steroids at induction of anaesthesia for adult tonsillectomy to reduce post-operative nausea and vomiting and pain: a double-blind randomized controlled trial. Clin Otorhinolaryngol. 2006;31(1):36-40.
21. Tewary AK, Cable HR, Barr GS. Steroids and control of post-tonsillectomy pain. J Laryngol Otol. 1993;107(7):605-6.
22. Fields M, Cabral D, Dawes P. The effect of DXmethasone on postoperative pain following tonsillectomy in adults. Aust J Otolaryngol. 1994;1:426-9.
23. Volk M, Martin P, Brodsky L, Stanievic J, Ballou M. The effects of perioperative steroids on tonsillectomy patients. Otolaryngol Head Neck Surg. 1993;109(4):726-30.
24. Carr MM, Williams JG, Carmichael L, Nasser JG. Effect of steroids on posttonsillectomy pain in adults. Arch Otolaryngol Head Neck Surg. 1999;125(12):1361-4.
25. Malde AD, Sonawane VS, Jagtap SR. Effect of DXmethasone on post tonsillectomy morbidity. Indian J Anaesth. 2005;49:202-7.
26. Splinter WM, Roberts DJ. DXmethasone decreases vomiting by children after tonsillectomy. Anesth Analg. 1996;83(5):913-6.
27. Erdem AF, Yoruk O, Alici HA, Cesur M, Atalay C, Altas E, et al. Subhypnotic propofol infusion plus DXmethasone is more effective than DXmethasone alone for the prevention of vomiting in children after tonsillectomy. Paediatr Anaesth. 2006;18(9):878-85.
28. Ohlms LA, Wilder RT, Weston B. Use of intraoperative corticosteroids in pediatric tonsillectomy. Arch Otolaryngol Head Neck Surg. 1995;121(7):737-42.
29. Fazel MR, Yegane-Moghaddam A, Forgiani Z, Aghadoost D, Mahdian M, Falharbrai E. The effect of DXmethasone on postoperative vomiting and oral intake after adenotonsillectomy. Int J Pediatr Otorhinolaryngol. 2007;71(8):1235-8.
30. Karaman M, Ilhan AE, Dereci G, Tek A. Determination of optimum dosage of intraoperative single dose DXmethasone in pediatric tonsillectomy and adenotonsillectomy. Int J Pediatr Otorhinolaryngol. 2009;73(11):1513-5.
31. Kim MW, Lee JH, Lee SC. The effect of DXmethasone in tonsillectomy. Korean J Otolaryngol. 1998;41:783-7.
32. Kim MS, Cote CJ, Cristoloveanu C, Roth AG, Vornov P, Jennings MA, et al. There is no dose-escalation response to DXmethasone (0.0625-1.0 mg/kg) in pediatric tonsillectomy or adenotonsillectomy patients for preventing vomiting, reducing pain, shortening time to first liquid intake, or the incidence of voice change. Anesth Analg. 2007;104(5):1052-8, tables of contents.
33. Elhakim M, Ali N, Rashed I, Riad M, Refat M. DXmethasone reduces postoperative vomiting and pain after pediatric tonsillectomy. Can J Anaesth. 2003;50(4):392-7.
34. Egeli E, Akkaya S. The effect of peritonsillar corticosteroid infiltration in tonsillectomy. Auris Nasus Larynx. 1997;24(2):179-83.
35. Smith JP, King JT, Gershon NI, Fisher WR. Alleviation of Pain and Prevention of Infection after Tonsillectomy: a Controlled Clinical Study of a Novel Injectable Combination. Trans Am Acad Ophthalmol Otolaryngol. 1964;68:65-9.
36. Liu CM, Su CY. Post-operative pain control with topical steroid injection after hot dissection tonsillectomy. J Laryngol Otol. 1996;110(11):1038-40.
37. Stewart R, Bill R, Ullah R, McConaghy P, Hall SJ. DXmethasone reduces pain after tonsillectomy in adults. Clin Otolaryngol Allied Sci. 2002;27(5):321-6.
38. Anderson HA, Rice BJ, Cantrell RW. Effects of injected deposteroid on posttonsillectomy morbidity: a double-blind study. Arch Otolaryngol. 1975;101(2):86-8.
39. Catlin FL, Grimes WJ. The effect of steroid therapy on recovery from tonsillectomy in children. Arch Otolaryngol Head Neck Surg. 1991;117(6):649-52.
40. Kim MW, Lee JH, Lee SC. The effect of DXmethasone in tonsillectomy. Korean J Otolaryngol. 1998;41:783-7.
41. Windfuhr JP, Chen YS. Incidence of post-tonsillectomy hemorrhage in children and adults: a study of 4,848 patients. Ear Nose Throat J. 2002;81(9):626-8, 30, 32 passim.
42. Windfuhr JP, Chen YS. Hemorrhage following pediatric tonsillectomy before puberty. Int J Pediatr Otorhinolaryngol. 2001 May 11;58(3):197-204.
43. Windfuhr JP, Schloendorff G, Baburi D, Kremer B. Serious post-tonsillectomy hemorrhage with and without lethal outcome in children and adolescents. Int J Pediatr Otorhinolaryngol. 2008;72(7):1029-40.
44. Catlin F, Grimes W. The effect of steroid therapy on recovery from tonsillectomy in children. Arch Otolaryngol Head Neck Surg. 1991;117(6):649-52.
45. Tewary A, Cable H, Barr G. Steroids and control of post-tonsillectomy pain. J Laryngol Otol. 1993;107(7):605-6.
46. Stewart R, Bill R, Ullah R, McConaghy P, Hall S. DXmethasone reduces pain after tonsillectomy in adults. Clin Otolaryngol. 2002;27(5):321-6.
47. Giannoni C, White S, Enneking FK. Does DXmethasone with preemptive analgesia improve pediatric tonsillectomy pain? Otolaryngol Head Neck Surg. 2002;126(3):307-15.
48. Celiker V, Celebi N, Canbay O, Basgul E, Aypar U. Minimum effective dose of DXmethasone after tonsillectomy. Paediatr Anaes-th. 2004;14(8):666-9.